BioCryst Initiate the Patient Enrolment in Proof-of-Concept Trial of BCX10013 for the Treatment of Complement-Mediated Diseases
Shots:
- The first patient has been enrolled in a proof-of-concept clinical trial evaluating BCX10013 for complement-mediated diseases. The trial focuses on evaluating the safety, tolerability, PK, PD & therapeutic potential of BCX10013 in ~15 adult patients with PNH
- The 1EPs of the trial are incidence of TEAEs, graded laboratory abnormalities, changes from baseline in laboratory analytes, vital signs, electrocardiograms & physical examination findings. The 2EPs will evaluate efficacy incl. change from baseline in LDH, PNH red blood cell to white blood cell clone size ratio, Hg level & proportion of patients who are transfusion-free, among other biomarkers
- The company seeks to advance into a pivotal program for renal complement-mediated diseases, incl. IgAN, if the results for PNH confirm a best-in-class profile
Ref: BioCryst | Image: BioCryst
Related News:- BioCryst Discontinues Development of BCX9930 for Paroxysmal Nocturnal Hemoglobinuria
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
Click here to read the full press release
Neha is a Senior Editor at PharmaShots. She is passionate and very enthusiastic about recent updates and developments in the life sciences and pharma industry. She covers Biopharma, MedTech, and Digital health segments along with different reports at PharmaShots. She can be contacted at connect@pharmashots.com.
